Table: Daito -2025/26 group results
10/07/2026 08:30
Jul 10 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
May 31, 2026 May 31, 2025 May 31, 2027 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 50.65 50.64 54.00
(+0.0 pct) (+8.0 pct) (+6.6 pct)
Operating 3.64 2.62 4.00
(+38.8 pct) (-32.7 pct) (+10.0 pct)
Recurring 3.81 2.71 4.00
(+40.9 pct) (-31.0 pct) (+4.9 pct)
Net
Net 3.16 1.91 3.00
(+65.7 pct) (-42.1 pct) (-5.1 pct)
EPS 107.49 yen 62.74 yen 104.37 yen
Ann Div 40.00 yen 70.00 yen 45.00 yen
-Q2 Div 20.00 yen 35.00 yen 22.50 yen
-Q4 Div 20.00 yen 35.00 yen 22.50 yen
NOTE - Daito Pharamaceutical Co Ltd.
*Second Net profit row denotes profit attributable to owners ofthe parent
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results